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ABSTRACT

C

OVID-19 has posed a considerable threat to all aspects of older Americans’ lives. The pandemic
generated acute illness, emergency department (ED) visits, hospitalization, respiratory failure,
and death. Pandemic-associated social isolation and loneliness further endangered older adults. Recovery from
COVID-19 illness has commonly been followed by chronic symptoms, which may also precipitate ED visits.
While vaccination has mitigated risks of serious illness requiring hospitalization, a booster dose is required to
sustain protection. New treatments and therapies, including monoclonal antibodies and antiviral agents, have
shown efficacy for older adults who are at risk of hospitalization. Older adults remain vulnerable in 2022, after
two years of the COVID-19 pandemic. Emergency care for older patients is now challenged with health system
staffing shortages and diminished access to care in community programs & skilled nursing facilities. This
article attempts to synthesize the avalanche of discovery and innovation into a narrative review
focused on the emergency and immediate post ED care of the aging adult patients both during and as a
result of the COVID-19 pandemic.
Box 1: Patient Scenario 1
An Older Patient Presents to the ED for Treatment
A 79-year-old Laotian woman who lives in the community with her family was seen by her primary care provider
at a routine follow-up visit in early January 2022. She was noted to have a cough with congestion. She had no loss of
smell and no gastrointestinal symptoms. She had no known sick contacts.
Past Medical History: Diabetes mellitus, osteoarthritis, peripheral neuropathy, depression, osteopenia, subclinical
hypothyroidism, and hypertension. She received a COVID vaccination (Feb and March 2021) but did not get a booster
dose. She needed assistance for bathing but otherwise was independent in her self- cares.
Medications include: lisinopril 5 mg daily, metformin XR 500 mg daily, vitamin D 2,000 units daily, atorvastatin 20 mg
daily, meclizine 12.5 mg daily prn, and gabapentin 100 mg each night. BP 173/96. Pulse 89/ minute. Pulse ox=97% on
room air. Respiratory rate= 20 per minute. Temperature= 98.6. BMI= 25. Physical examination was remarkable for
normal attention and level of consciousness. Her cardio-pulmonary examination was normal. Her COVID-19 test in the
primary care office was positive.
•

Which medication or treatment could be considered?

•

How would you counsel the patient regarding her co-morbid illnesses?
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Box 2: Patient Scenario 2
An Older Patient Presents to the ED with a Cascade of Symptoms and Functional Decline after COVID-19
A 73-year-old community-dwelling woman was brought to the ED by her daughter who reports that the patient
had a decline in function and cognition after her recent hospital discharge. Her daughter reports having trouble
managing her at home. The patient was noted to be sleeping all day, and not eating. She was generally weak and
complained of pain in both of her legs. She missed her most recent dialysis, as she was too tired. She required two
family members to assist with transfers. Prior to her hospitalization, she required only one person to assist.
Fourteen days ago, her family brought her to the ED 3 days after testing positive for COVID-19. She received no
vaccination for COVID-19. At that time, her symptoms included a runny nose, cough productive of green sputum, and
nausea. There was no hypoxia. She had missed dialysis once due to difficulty coordinating care with active COVID-19
infection. Her initial admission labs were significant for hypokalemia and hyponatremia. Physical therapy and
occupational therapy noted a decline from her baseline function. Her recent hospital length of stay was 3 days.
Past Medical History: Multiple co-morbidities included ESRD (receiving dialysis on T/Th/S), dementia, cerebrovascular
accident, atrial fibrillation, coronary artery disease with NSTEMI in 2020, hypertension, osteoarthritis, and proteincalorie malnutrition. Her multiple medications included apixaban.
Social history was notable for the daughter being her paid personal care provider.
The ED was overcrowded with 20 boarding admitted patients.
•

What are common problems for older patients with recent COVID-19 infections?

•

How would you determine the best strategy to help this older patient and her family caregivers?

•

How do we access community and long-term services to support this patient and family caregiver?

BACKGROUND
During the last two years of the COVID-19 pandemic, the emergency department (ED) has been
the interface between our community and our health care system. As of March 13, 2022, over 79.5 million
cases and 967,711 deaths have been attributed to COVID-19 in the United States (US).1 This paper will
provide key points about COVID-19 in older adults for emergency medicine providers, as exemplified in
the case scenarios (Boxes 1 and 2). We will present a succinct review of COVID-19 epidemiology in older
adults and review the presentation of both acute illness and the sequelae of COVID-19 illness. We will
review reports of vaccination protection in older adults, ED treatment strategies, and the implications of
COVID-19 on systems of care affecting older patients. Finally, we will describe the impact of the pandemic
on the ED workforce.

EPIDEMIOLOGY
Age is associated with severe COVID-19 outcomes. More than 54.1 million people are aged ≥ 65
years in the US. In 2020 these older persons suffered 81% of U.S. COVID-19 related deaths, and as of
September 2021, their mortality was over 80 times greater than those aged 18-29 years.2,3 Although
residents in long-term care facilities made up < 1% of the U.S. population, those residents suffered 16% of
all COVID-19 deaths.4-8 Additionally, the COVID-19 mortality risk and disease severity associated with
any high-risk condition increases with age.9,10 Lastly, older adults infected with COVID-19 were more
likely than younger adults to require hospitalization, develop pulmonary failure, and need either noninvasive or invasive ventilation.11
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ACUTE PRESENTATION OF COVID-19 IN OLDER ADULTS
COVID-19 is a multi-organ disease and therefore causes a broad spectrum of signs and
symptoms.12 COVID-19 patients typically exhibit nonspecific symptoms of both upper and lower
respiratory infection along with occasional nausea, vomiting, and diarrhea. One population screening
study of 1,279 people demonstrated that fever, ageusia (loss of sense of taste), and weakness increased the
odds of infection, while 36% of people testing positive were asymptomatic.13
In a Cochrane review of 44 studies, including 10 from the ED, only cough and fever had a
sensitivity of at least 50% for COVID-19 illness.14 These studies used a positive RT-PCR as the reference
standard, as well as clinical expertise and imaging. The presence of anosmia (loss of sense of smell) or
ageusia had sensitivities below 50% but, specificities of 93%. However, the majority of signs and
symptoms heralding potential COVID-19 infection had very poor diagnostic accuracy. Neither the
presence nor absence of commonly attributed COVID-19 symptoms were accurate enough to be predicative
or capable of excluding active illness. However, simple fever and cough may be useful to identify people for
further testing, and the presence of anosmia or ageusia can serve as “red flags” for acute illness. There is a
paucity of solid evidence for diagnosis of COVID-19 in older adults. COVID-19 signs and symptoms along
with most serious infections in this population such as bacterial pneumonia, and urinary sepsis, all lead to
non-specific presentations. The older adult’s presenting signs and symptoms can be used with diagnostic
testing during the acute presentation in the ED. Notably, however, a negative RT-PCR test does not rule
out COVID-19 and should not be used as the sole basis for treatment or management decisions. A falsenegative test could occur if testing was performed too early or too late to make an accurate diagnosis with
the RT-PCR.15
The categorization of potential illness into actionable groups based on illness severity is more
impactful to the emergency clinician.16,17 Mild or moderate illness symptoms include fever, cough, aches,
and lethargy without dyspnea at rest. Severe symptoms include dyspnea, tachypnea, and hypoxia, with
features ranging from pneumonia to acute respiratory distress syndrome (ARDS), shock, or other organ
dysfunctions. Kennedy and colleagues documented that delirium often existed without any other typical
signs or symptoms of COVID-19 infection.18 Delirium was also associated with poor hospital outcomes and
death. Delirium should therefore be considered as an indication for screening, testing, and evaluation for
COVID-19 infection in older adults.

LONG-HAUL PRESENTATION OF COVID-19 IN OLDER ADULTS
Descriptions of post-acute sequelae lasting beyond 12 weeks have been termed post-COVID-19
syndrome or long-haul COVID.19 Long-haul COVID incidence is predictably rising following high rates of
omicron infection. Easy fatigability is the most common symptom of this COVID-19 complication. One
study noted fatigability in 51% of those with long COVID findings. Anxiety, dyspnea, and headache were
each noted in 38%.20 Most studies followed a cohort of patients 60 days after their diagnosis, symptom
onset, or hospitalization; or for 30 days after their recovery or hospital discharge. Studies typically use
surveys imaging and/ or diagnostic clinical assessments outside of the ED.21 ED physicians and nurses
should be aware that in some patients, symptoms may persist long after recovery from COVID-19. To
make the diagnosis of long haul COVID-19 in older adults in the ED, the clinician would need to assess for
a functional decline during the COVID-19 illness or find an acute illness that could explain the symptoms.
In one bit of favorable news for older adults, they are less likely than the younger cohort to
experience post- COVID psychological distress such as PTSD, depression, and anxiety.22 Older adults
generally exhibit higher levels of resilience to pandemic-related psychological stress.23,24 In cognitively
intact older adults, age may buffer COVID-19 related mental health deterioration.25 Yet the harms of
social isolation were not examined in these studies.
Older adults demonstrate higher rates of cognitive difficulties, persisting for months after
discharge from COVID-19 hospitalization.26 New onset dementia has been noted in about 2% of patients
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over age 65 in the first 14-90 days post- COVID-19 diagnosis.27 This new dementia may cause increased
ED presentations and require increased home supports to allow ED discharge. Enhanced access to
cognitive screening from the ED should be considered for older adult COVID-19 survivors. Further
research of long-haul COVID-19 will need to be integrated into ongoing research on ED dementia care.28

TREATMENTS AND MANAGEMENT IN THE ED
Therapy
The use of ethical principles such as maximizing benefit to the greatest number, preventing harm,
and mitigating health inequities, may allow ED prioritization for access to new therapies with limited
availability.29 Shared decision-making in the ED is fundamental during the care of older adults.30,31 ED
providers have learned from pandemic resource shortages that the time to develop these strategies is
before the next wave of illness outpaces resources.32
The ED management of COVID-19, as with all illnesses, focuses first on stabilization of life
threats. In COVID-19, the first and most important mainstay of treatment is supplemental oxygen.
Supplemental oxygen can render patients eupneic, greatly reducing the potential for respiratory
exhaustion.33 Advanced age is associated with a high risk of pulmonary failure, need for mechanical
ventilation, and death. Age ≥ 85 years, dyspnea, and polypharmacy are important predictors of
mortality.34 The amount of supplemental oxygen reaching the alveoli maximizes at a FiO2 of 44%, with
flows in excess of 6L.35 FiO2 can be increased to 100% when used with a 10 -15L/min flow rate.36 Oxygen
delivery may be further increased by high flow nasal cannula (HFNC) devices, which maintain FiO2 at
100% while increasing flow to as much as 60L/min.37 The use of high-flow oxygen through a nasal cannula
significantly decreased the need for mechanical ventilation support and time to clinical recovery compared
with conventional low-flow oxygen use.41, 42
If patients remain hypoxemic despite maximal therapy with HFNC, they are typically placed on
higher levels of support such as CPAP or invasive mechanical ventilation (IMV). One study showed HFNC
use effectively prevented IMV in 71.4% of patients.38 Another study showed that one-third of hypoxic
COVID-19 patients on HFNC did not require intubation.39 Cochrane review determined that HFNC likely
improves treatment compared to standard oxygen but makes little or no difference to treatment failure
compared to NIV or NIPPV. Comfort is of particular importance in tolerating any therapy in cognitively
impaired individuals. It is important that improvement in either short-term or long-term comfort with
HFNC proved of very low certainty.40 Among patients with severe COVID-19, HFNC seems to be an
effective and safe treatment modality in acute respiratory failure.

Vaccination
A paucity of older individuals was studied in published and ongoing phase II-III randomized
clinical trials evaluating COVID-19 vaccine efficacy. We know older people suffered the highest
consequences of morbidity and mortality from COVID-19. They were also the first population to be
vaccinated. This resulted in a large population available for a vaccine efficacy study. However, only 9.83%
of any study participants were ≥ 65 years, 1.66% ≥ 75 years, and < 1% were ≥ 85 years.43 Also striking is
the lack of studies supporting the efficacy and safety of COVID-19 vaccines on older persons with frailty,
disability, or living in long-term care facilities.44 A recent study examined the immunogenicity and
adverse reactions of BNT162b2 mRNA vaccines in older adults with frailty or living in long-term care
facilities. The vaccine produced immunogenicity, independent of age, or level of frailty and co-morbidity.
The small sample size and inclusion criteria are cause, however, for further study.45
As of March 13, 2022, 91.3% of adults aged 65 to 74 years and 85.6% of adults age ≥ 75 years are
fully vaccinated for COVID-19.46 The immunization of older people with either mRNA or vector-based
vaccines decreased the likelihood of severe cases needing ICU care by more than 90%.47 In adults ≥ 50
years two doses of mRNA vaccine demonstrated 89% effectiveness against laboratory-confirmed infection
requiring hospitalization, 90% effectiveness against ICU admission, and 91% effectiveness regarding ED
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or urgent care clinic visit. Two vaccine doses provided protection in persons ≥ 85 years varying from 8195% for hospitalization, ED, or urgent care clinic visits. Given the concern for impaired immune response
with aging these data are encouraging.48 Vaccinations did not entirely prevent post-vaccination COVID19 infections, termed breakthrough infections. Seventy percent of breakthrough infections requiring
hospitalization occurred in adults ≥ 65 years. Older persons also accounted for 87% of breakthrough
mortality.49 However, the majority of breakthrough infections in post-vaccinated patients were mild or
asymptomatic.50

Boosters
In older patients, the risk of COVID-19 illness increases six months after the initial vaccination.
Decreased protection against hospitalization and death was greater in those ≥ 65 years at 20 weeks or
more after vaccination. Greater waning of effectiveness against hospitalization was noted with the delta
variant and with the increase of clinical vulnerability.
However, booster vaccination rapidly induces a recurrent and robust immune response. This was
found across all ages, with older adults defined as age ≥ 60 years of age.51-54 The administration of a third
COVID-19 mRNA vaccine dose improved protection against COVID-19 associated hospitalization.55
Omicron variant infection outcomes were also improved by booster vaccination doses. As of January 8,
2022, infection incidence and hospitalization, and mortality rates were lowest in those having booster
doses.56 People receiving a booster at least 5 months after a second vaccine dose had 90% lower COVID-19
mortality.57 Rates of severe illness were lower in the ages ≥ 60 years booster group, by a factor of 21.7%.51
Importantly, longer intervals between doses provided higher serologic responses and increased
vaccine effectiveness.58 An optimal dosage interval has yet to be reported. Heterologous boosting is
defined as the administration of the booster dose from a different manufacturer than was given in the
primary series. Heterologous vaccination in all adults, including those > 61 years, resulted in more robust
immune responses than homologous boosting and might enhance protection.59
On March 15, 2022, Pfizer and BioNTech sought authorization from the Food and Drug
Administration for a second COVID-19 booster shot for older Americans.60
Several strategies have been suggested to enhance vaccination acceptance in older adults. The
Society of Academic Emergency Medicine presents resources for overcoming barriers to vaccination.17
Additionally, healthcare workers can enhance vaccination in this population by the incorporation of
known communication strategies, questions, and prompts.61 Novel vaccine platforms and adjuvant
systems should be considered to enhance the vaccination in older adult populations.62 We encourage ED
systems to routinely offer COVID vaccination, especially since EDs routinely provide vaccination for
illnesses of far less public health impact, such as tetanus.17 The offer of a vaccine for respiratory
transmissible infection may have greater acceptance in patients presenting to the ED with concern, but
testing negative for, the illnesses of influenza or COVID. Lastly, a global strategy enhancing older adult
immunization as part of a public health agenda could decrease the suffering for the billions of older
persons at risk of death and disability from vaccine-preventable diseases.63

TREATMENT RESOURCES FOR ED PROVIDERS
Therapies for the treatment of COVID-19 are still in development with no effective curative
therapy yet available. Table 1 describes COVID-19 treatment and resources for older adults. 17, 64-70 Most
of the guidelines and websites describe evidence-based care, without overtly defining older adult
considerations. The Infectious Disease Society of America site,65 and the WHO site,68 note specific older
adult considerations. The geriatrics portion of the American College of Emergency Physicians COVID-19
Management tool,64 provides information from the early pandemic. The Society of Academic Emergency
COVID Provider Toolkit,17 provides succinct communication strategies, as well as interactive treatment
recommendations. Finally, a side-by-side tool from the Health and Human Services is a clinician-friendly,
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graphic depiction of considerations for prescribing and administering treatments for those with mild to
moderate COVID-19.70
Table 1: COVID-19 Treatment and Resources for Older Adults
Resource

Date Updated

Geriatric EM Centeredness

Components of the Resource

Site

ACEP COVID-19
Field Guide 64

July 13, 2021
Geriatrics section
from early in the
pandemic.

One chapter in this resource was
specific to older adults-social
isolation; inter-facility transfers.

https://www.ace
p.org/corona/co
vid-19-fieldguide/coverpage/

Infectious Disease
Society of
America RealTime Learning 65

March 8, 2022
Geriatrics section
updated November
9, 2021.

NIH COVID-19
Treatment
Guidelines 66

March 2, 2022

The European
Society of Clinical
Microbiology and
Infectious
Diseases COVID19 Living
Guidelines 67
WHO Living
COVID-19
Guideline 68

February 1, 2022

Geriatrics was included within
patient populations. Key areas
included delirium, frailty,
dementia, and clinical features
plus resources.
The approach for older adults
was integrated into the
guidelines, but not defined in
special populations. A succinct
description was provided on
follow-up after ED care.
No specific recommendations
for older adults in special
populations. The approach to
older adults was not integrated
into the guidelines.

General descriptions of
presentation of illness and
systems-based ED strategies early
during the first wave of the
pandemic.
Table and clear outline helped to
synthesize the treatments, the
setting of care, the
recommendations, and the
certainty of evidence.
A detailed website with guidelines
in the context of care. The
summary of recommendations
was helpful.
Ratings of evidence and ratings of
recommendations were provided.
Regularly updated guidelines with
detailed data tables which provide
a synthesis of evidence. Clinical
questions focused on population,
intervention, comparison, and
outcomes (PICO). Difficult to
navigate the resource tables.
Well-written synthesis of evidence
with easy-to-navigate pdf and
website. Recommendations for
clinical management scenarios.

US Federal
Response to
COVID-19
Therapeutics 69

February 15, 2022

This resource focuses on the mild
to moderate COVID-19 in high-risk
patients. Includes a graphic
summary of the setting of care
with treatment considerations.

Health and
Human Services
Side by Side
Overview of
COVID-19
Therapeutics 70

March 1, 2022

Geriatrics considerations are
noted, including adjustment for
renal impairment, drug-drug
interactions, and Medicare
coverage.

https://www.ph
e.gov/emergenc
y/events/COVID
19/investigationMCM/Document
s/USG-COVID19Tx-Playbook.pdf
https://aspr.hhs.
gov/COVID19/Therapeutics/
Documents/sideby-sideoverview.pdf

Society of
Academic
Emergency
Medicine COVID19 Provider
Toolkit 17

January 3, 2022

Strategies to improve
communication with older
adults are integrated into the
materials.
Treatment recommendations
are not specific for older adults.
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November 23, 2021

A thoughtful and succinct area
of this guideline described
practical considerations for
assessment and care of older
adults with COVID-19.
No specific description of the
unique needs of older adults,
beyond renal disease and drugdrug interactions for Paxlovid.
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A quick reference for outpatient
therapies for prevention of COVID19 infection or treatment of mild
to moderate COVID-19. The
simplicity of the tool allows for
details of how to prescribe each
treatment/ medication.
This interactive website provides
(evidence-based) succinct
treatment recommendations as
well as strategies to improve
communication with patients who
have COVID-19.

https://www.ids
ociety.org/covid19-real-timelearningnetwork/
https://www.cov
id19treatmentgu
idelines.nih.gov/

https://www.clin
icalmicrobiology
andinfection.co
m/article/S1198743X(21)006340/fulltext

https://www.wh
o.int/publication
s/i/item/WHO2019-nCoVclinical-2021-2

https://www.sae
m.org/education
/saem-onlineacademicresources/covid19-providertoolkit
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Monoclonal Antibody (mAb) Treatments
Monoclonal antibody (mAb) treatment is associated with decreased hospitalization and death in
outpatients with mild to moderate COVID-19.71-74 Older age is an indication for mAb treatments.70 These
treatments are especially important for ED providers discharging patients home with mild to moderate
COVID-19 symptoms. We will not describe the mAb treatments which are not likely to be active against
the omicron variant and limit our focus to sotrovimab.
•

•

Sotrovimab treatment has resulted in a 79- 85% reduction in hospitalization or death in high-risk
adult outpatients compared to placebo.75 This drug has activity against the Delta variant and is likely
active in the Omicron variant.68 Sotrovimab, similarly to the other mAb treatments, is authorized
only for the treatment of lab-confirmed mild to moderate disease within ten days of symptom onset.
See Table 2.
Monoclonal antibody treatments are an effective treatment for those with laboratory-confirmed
COVID-19 who are ≥ 65 years. Additionally, they may be used for younger patients at high risk of
progressing to severe illness.70 See important details that refer to eligible populations. These
treatments are NOT authorized for hospitalized patients nor for those who require oxygen therapy.
Recommendations for monoclonal antibody medication are often made at a regional/local level, based
on the treatment that best covers local variants.

Therapy with monoclonal antibodies changes rapidly subject to the latest available evidence and
guidance of the Center for Disease Control. These therapeutics are distributed via the HHS Office of the
Assistant Secretary for Preparedness and Response transitioned to a State and Territory-coordinated
Distribution System for mAbs.76

Oral Antivirals
•

•

Paxlovid has shown an 88% reduction of hospitalization or death for high-risk patients if given within
5 days of symptom onset.69,70 It has known activity in the Delta variant and data is pending on
Omicron variant activity. Table 2 highlights the high risk of drug-drug interactions and comorbid
illnesses which is relevant to older adults. The percentage of older adults in the clinical trial was low.
Molnupiravir has shown a 30% reduction of hospitalization and death for high-risk patients if given
within 3 days of symptom onset. It has known activity in the Delta variant and data is pending on
Omicron variant activity.77 In a phase 3 trial of 1,433 persons who were unvaccinated with mild to
moderate laboratory-confirmed COVID illness and at least one high risk factor for severe disease,
molnupiravir reduced the risk of hospitalization or death when started within 5 days of symptoms.78
The effectiveness of molnupiravir is competitive to the three monoclonal antibodies remdesivir and
nirmatrelvir-ritonavir, with a relatively lower cost.79 An FDA expert panel review showed that
molnupiravir with 50% hospitalization reduction was inferior to the three existing monoclonal
antibody cocktails having over 60% efficacy. However oral availability and decreased expense of
molnupiravir lead to ultimate approval recommendation.80 Table 2 highlights the low rate of older
adults in the clinical trial of this medication.

Other Treatments
•

Remdesivir has mixed data on efficacy against COVID disease progression. One study shows that a 3day course resulted in 30% of patients > 60 years with 87% lower hospitalization risk or death, and an
acceptable safety profile.81 Please see Table 2. Another trial concluded that remdesivir shortened the
time to recovery in hospitalized patients with lower respiratory tract infections.82 However, a Cochrane
review found moderate certainty that remdesivir has little or no effect on all-cause mortality at up to
day 28 in hospitalized adults with SARS-CoV-2 infection.83 Finally, one study showed an association
with longer hospital stays.84
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•

•

Convalescent Plasma (CP) some studies demonstrated that early administration of high-titer CP
reduced the progression of COVID-19 in mildly ill older adults.85 An October 2020 Cochrane review
update detailed the uncertainty of the benefit of CP treatment.86 Finally, a December 2021 scoping
review included 154 studies- with 112 studies concluding CP is safe and resulted in clinical
improvement.87
Steroids, in patients hospitalized with COVID-19, the use of 6 mg daily of dexamethasone resulted in
lower 28-day mortality among those who were receiving either invasive mechanical ventilation or
supplementary oxygen, but not among those who did not need respiratory support.88 In the
RECOVERY study no benefit of the use of steroids was observed in patients of older age or higher
number of co-morbidities.89 The use of dexamethasone resulted in a 30% reduction in 28-day mortality
among patients receiving invasive mechanical ventilation compared to the usual care group. No
benefit was found among patients not requiring respiratory support. The WHO strongly recommends
corticosteroids (i.e., dexamethasone, hydrocortisone, or prednisone) for the treatment of patients with
severe and critical COVID-19.68

Table 2: COVID-19 Treatments for Older Adults
Percent of Older
Adults in Clinical Trials
No detail provided on
% age >=65 years.
Median age= 60 years.
Range 50-69 years.

Setting

Treatment

ED +
Hospital

High-flow O2

ED +
Outpatient

Monoclonal
antibodies
sotrovimab.

22% were age >=65
years and 11% were
>=70 years.
Median age= 53 years.
Range 18-96 years.

ED +
Outpatient

Oral Antiviral
Paxlovid
nirmatrelvir/
ritonavir

13% were age >=65
years and 3% were
>=75 years.
Mean age= 46 years.

NNT=17.5 to prevent
1 hospitalization for
any cause through day
28.
Harms: No deaths in
the treatment group
and 1.6% deaths in
patients receiving
placebo.

ED +
Outpatient

Oral Antiviral
molnupiravir

34% were aged >=50
years.
Median age=43.0
years.

NNT= 14.7 to prevent
1 hospitalization for
any cause or death
through day 29.
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*Benefits/ Harms

Nuances for Older Patients

NNT= 6 to avoid 1
endotracheal
intubation in adults
with acute respiratory
failure and severe
COVID-19.
NNT=16.7 to prevent
1 hospitalization for
any cause or death.
Harms: Approximately
1% risk of transfusionrelated reaction.

High-flow oxygen therapy in the ED and
intensive care unit decreases the need for
endotracheal intubation and shortens the
time of clinical recovery in severe COVID-19
when compared to conventional low-flow
oxygen therapy.42
For the treatment of mild-to-moderate
COVID-19 in adults and pediatric patients
(12 years of age and older weighing at least
40 kg) with positive results of direct SARSCoV-2 viral testing, and who are at high risk
for progression to severe COVID-19,
including hospitalization or death.75
Treatment should be given as soon as
possible, within 10 days of onset of
symptoms.
No adjustment for renal function.
Must have immediate access to
medications to treat severe infusion
reactions/anaphylaxis.
For mild to moderate COVID-19 in adults
with a positive test for the virus, who are at
high risk for progression to severe COVID19 including, hospitalization and death.69,70
Start as soon as possible following
diagnosis, and within 5 days of symptom
onset.
Renal dosing required.
Avoid in eGFR <30 ml/min.
Multiple/serious drug-drug interactions
related to ritonavir a strong cytochrome
P450 (CYP) 3A4 inhibitor metabolism.
For treatment of mild to moderate COVID19.78
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ED
infusion

Early
intravenous
remdesivir
daily for 3
days.

Range 18-90 years.

Harms: No safety
concerns when
compared to placebo.

30% were aged >=60
years.
Mean age= 50.0 years.

NNT= 21.7 to prevent
1 hospitalization for
COVID-19 through day
28.
Harms: adverse events
occurred in 12.2% of
the remdesivir group
and 8.8% of the
placebo group.

Start as soon as possible following
diagnosis, and within 5 days of symptom
onset.
Renal dosing not required.
For symptomatic non-hospitalized patients
with COVID-19 who are at high risk of
disease progression.81

*The number needed to treat was calculated from each original citation. The control group outcome minus the intervention group outcome
was equal to the absolute risk reduction. The number needed to treat is the inverse of the absolute risk reduction.

PSYCHO-SOCIAL IMPLICATIONS FOR OLDER ADULTS DURING THE PANDEMIC
Social isolation and loneliness have been important health challenges for older adults during the
COVID-19 pandemic.90, 91 Social isolation and loneliness are major risk factors linked with poor physical
and mental health status. Mandates for stay at home and social distancing have exacerbated social
isolation and loneliness. Economic insecurity, difficulty accessing health care services, and racial
inequities compound the situation. Some innovative voice-controlled intelligent technologies have been
implemented to counteract COVID- era loneliness.92 Emergency medicine physicians seldom recognize
social isolation and its detrimental impact on the daily lives of vulnerable older adults.93
Many older adults presenting to the ED may not have left home or had any interaction with a
medical provider for weeks to months. The ED is often the site where family caregivers turn when they
are unable to care for their loved ones. Efforts to identify medical problems are improved by an
assessment of the individuals’ social supports and their access to community resources. Knowledge of
these supports is critical for safe discharge in this population.
If the ED assessment shows that the patient does not require admission to the hospital, it is
imperative providers understand the availability of current community resources. The pandemic has
limited available usual resources, especially personnel. Typical orders for home care or other support
services may not be available. A shortage of resources is a common theme. Community programs may be
in short supply, including non-medical home care, transportation, community meal sites, behavioral
health programs, in-person counseling, and aging services from the county to support family caregivers.
Skilled home care agencies have, likewise, faced an increase in referrals with a lack of staff to provide the
services. Table 3 shows how ED physicians can access community resources for older adults. Knowing and
acting on what matters most to the older person honors the individual’s choices.94

CARING FOR INDIVIDUALS WITH ALZHEIMER’S DISEASE OR RELATED DEMENTIAS
The number of older adults in the U.S. living with dementia or related disorders has increased
with continued rise projected in the coming decades.95, 96 Therefore, ED teams are increasingly more likely
to evaluate and treat individuals living with dementia.97
Individuals living with cognitive challenges often experience negative effects from busy ED
environments. Loud noises, bright lights, overcrowding, and long waits to be seen, admitted, or discharged
may all contribute to sensory overload and increased anxiety. In addition, building rapport quickly with
unfamiliar providers may be difficult for individuals with mild, moderate, or advanced dementia.98 These
challenges have precipitated the need to improve dementia care in the ED and the evidence base on which
to provide that care. GEAR 2.0 ADC provides recommendations for screening, communication, best care
practices, and care transitions.28
COVID-19, isolation, and limited social interactions have contributed to reduced physical activity,
depression, and loneliness among older adults and care partners.99, 100 Limited physical activity and social
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isolation also contribute to accelerated cognitive decline.101 As a result, family stress levels are heightened.
Care partner capacity often influences whether or not a person living with dementia is taken to the ED or
if they can return to their home or community safely.102
The challenges of living with an older adult who is experiencing symptoms related to dementia
have increased, and many care partners accompanying a person with dementia to the ED show signs and
symptoms of weariness, anxiety, and exhaustion. In some cases, family or other care partners become ill
themselves or are unable to find a paid caregiver due to the current staffing crisis.103
Unfortunately, while many low or no-cost programs and services exist in most communities, ED
staff members may not be aware of them, or may not have resources to make helpful referrals to support
families.104, 105 An interprofessional team approach has been effective106 where social workers or care
managers assist in providing information on community resources and follow up with primary care
providers and/or dementia specialists. Reduced social worker or care manager hours in the ED limits
patient or care partner access to the individuals on the team who are most familiar with community
services such as Area Agencies on Aging (AAAs), senior centers, nutrition programs, home care agencies,
and others. Table 3 provides online search tools for local community resources for older patients and their
family caregivers.
Table 3: Community Resources to Safely Assist Older Adult Returning Home from the Emergency Department
Resource
Eldercare Locator

Services
Housing, transportation,
services, and support
services.

Older Veterans
Services

Veterans Health Care for
Elderly Veterans.
Pension information.

Alzheimer’s
Association

Caregiver support groups,
counseling, and 24/7
Helpline.

Find Help.org

Community-based
organizations and resources
for food, housing,
transportation, etc.

Description
This user-friendly website
from the U.S.
Administration on Aging
provides a link to local
community resources
based on the individual’s
zip code.
This website provides links
to Veterans Affairs
benefits and services with
searchable resources
based on the Veteran’s zip
code.
This website provides
resources to support
family caregivers of
individuals who have
Alzheimer’s disease and
related dementias.
A free online tool to find
social services by zip code.
Developed by
auntbertha.com.

How to Access the Resource
https://eldercare.acl.gov/Public/Index.aspx

https://www.benefits.va.gov/persona/vetera
n-elderly.asp

https://www.alz.org/

https://www.findhelp.org/

CHALLENGES FOR RESIDENTIAL CARE CENTERS AND IMPLICATIONS FOR TRANSITIONS
Recruiting and retaining qualified staff, particularly clinical staff providing hands-on care, has
been a challenge in nursing facilities and assisted living facilities for many years. High rates of staffing
turnover in positions of nurses and nurse aides, are well documented and have been correlated with
quality concerns, including citations related to infection control.107 A recent article found that the average
annual turnover rate for total nursing staff in these facilities was 128%.108 Now, the situation is even
more critical.109 As in many healthcare settings, burnout has led to clinical staff leaving the front lines. In
addition, nursing facilities are competing with hospitals and staffing agencies that are offering significant
financial incentives. While most nursing facility staff have received the COVID-19 vaccine, some staff
have left employment in certain facilities due to vaccine mandates. A small, 50-bed nursing home may
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only have four nurses on staff and if two are unvaccinated and choose to leave their jobs this can have a
significant impact on that facility.
Inadequate staffing contributes to increased ED transfers. Staffing levels may also impact the
ability of nursing facilities to receive patients from the ED or following a hospital stay.110 While the overall
census of most nursing facilities is down, which would indicate a capacity for additional patients, short
staffing forces some administrators to pause taking admissions. Patients who are COVID positive can be
discharged to nursing facilities, and facilities often create dedicated COVID wings or sections. Depending
on whether they have an active outbreak and ability to dedicate staff to the COVID unit, a given facility
may decline to accept these transfers. This can lead to longer wait times for patients prior to discharge
and have a ripple effect on ED and hospital bed capacity. Further, a patient who meets the criteria for
nursing facility level care may refuse to transfer to the setting, which can also delay discharge planning.
Coordinating care at times of transition is a persistent challenge across the healthcare system.
Table 4 provides a checklist of factors the ED should consider before transferring back to a long-term care
facility. Older adults are particularly vulnerable to adverse events during such care transitions. These
may include adverse drug events or medication errors, falls, abuse or neglect, pressure ulcers, and
dehydration. The use of systematic approaches, such as checklists and warm handoffs, and calling the
next site of care to ensure a coordinated transition, is even more essential. 101
Table 4: A Checklist of Ten Factors the ED Should Consider Before Transferring a Patient Back to a Long-Term Care
Facility
Checklist Item
1. Stable vital signs and
oxygenation.
2.
3.
4.

5.

The patient’s advance
directives.
“What matters most in the
individual’s health?”
Provider understanding of
which site in the long-term
care setting patient receives
care.
Adequate staffing available at
the long-term care facility.

6.

Cognition and function back to
baseline.

7.

Able to eat and drink and take
medications.

8.

Access to new medications.

9.

Follow up in a timely manner.

10. Communicate with a warm
handoff, prior to transfer back.
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Succinct Rationale
An indicator of the severity of illness, comorbid conditions, and response to
treatment.
A clear indicator of who is making the
health decisions.
Understand the patient’s preferences
and develop a care plan that matches.
Multiple services may be available
within many retirement facilities.

Mitigation Strategy
Observe or admit; provide oxygen.

Staffing levels at the outlying facility
may block their ability to receive
patients back from the ED.
Delirium and functional decline are
common during acute illness and COVID19.

Real-time communication strategies to
clarify: if the facility can receive patients;
contact information; policies.
Screen for delirium and avoid transfer for
those with delirium. Assess baseline and
current function and avoid transfer for
those with significant new functional
change.
Observe or admit.

Loss of the ability to take oral intake
blocks hydration, nutrition, and
management of co-morbid conditions.
Inability to start new medications from
the ED would block the initiation of a
care plan.
Inability to provide follow-up of a new
condition would block the ability to
monitor the response to a new
treatment.
A succinct description of what was
found and the care plan.

Review Article

Clarify and honor how the patient wants
to receive care.
Review advanced directives and discuss
with the patient.
Consult social services to define where the
individual receives care and what is
needed/available after the ED visit.

Have a list of long-term care sites and
meds available.
Communicate with the primary care
provider and describe the care plan.

A quick call to the long-term care facility
or secure chat in the electronic health
record.
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CHALLENGING ASPECTS FOR EMERGENCY DEPARTMENT STAFF
During the COVID-19 pandemic, frequently changing recommendations and requirements from
the CDC, CMS, individual state departments of public health, and other agencies have created a
particular challenge for the care of patients who are in acute distress, unstable, and require immediate,
life-saving treatments.112 Optimizing ED staff and patient safety under those conditions challenges our
daily use of personal protective equipment (PPE), types and fit of masks, and frequency of staff testing.
Additional issues are caused due to the availability of testing and treatment resources, vaccination and
booster requirements, and other public health measures.
ED physicians and nurses, know that the last two years of serving on the frontline of an
increasingly strained health care system has been exhausting. Our patients are sick, tired from long
waits to be seen, and then are often boarding excessive amounts of time in the ED. It has been
challenging if not impossible to care for them in the ways we want and which they deserve.
Our hospitals are strained to the breaking point and often unable to admit those requiring
admission nor to support ED staff in managing patients to the extent needed. Many of the community
resources we depend on for patient support have closed during COVID-19. We have been asked to keep
visitors out of the ED, often causing confrontational conversations with patients’ loved ones. All the while
we are worried about getting ill ourselves from a poorly understood or infecting our loved ones with a
potentially deadly virus. There are no perfect answers but here are a few best practices shared by our ED
colleagues from around the world.

Take care of yourself (self- wellness).
Emergency physicians now rate the highest amongst all specialties in burnout and depression.113
The same may well be true for emergency nurses. We need to recognize just how hard our jobs currently
are and take time for wellness activities. Also, we need to encourage our colleagues to do the same.

Bring caregivers in.
Caregivers (care partners) are not visitors.114 Patients, especially patients with cognitive
impairment, need their caregivers. The caregiver is often the ED staff’s best ally and will help in the
provision of collateral history as well as in the care of the patient. Caregivers can provide re-orientation,
assist with feeding and toileting to decrease delirium development in older patients and stress on ED
staff. Help your hospital recognize that caregivers are not visitors by allowing appropriately screened
caregivers into the ED with PPE.

Enable everyone on the team to work at the top of their license.
There are many skilled individuals that can help ED performance if we let them. Some EDs are
bringing paramedics into the ED to help place IV lines and administer medications.115 Other EDs are
using medical or nursing students as vulnerable patient ambassadors who can help ensure that those
without caregivers have their needs met. Look around and see who your system can offer to help you.
While ED staff often assist with any and all patient care functions as part of the team, it is not optimal to
have physicians drawing or sending labs, nor nurses cleaning floors. Keeping professionals functioning at
their maximal professional capacity and having adequate support personnel is our goal for both optimal
ED functioning and professional satisfaction.

CONCLUSION
The COVID-19 pandemic has greatly impacted ED care of older adults. Nonspecific symptoms
and alterations of mental status are common presentations in both acute and long-haul COVID-19.
Categorization into disease severity groups is useful for both treatment and disposition.
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Supplemental oxygen is a mainstay of ED stabilization and applies equally to older persons.
Vaccinations and boosters are lifesaving and reduce ED visits, especially in those most vulnerable.
Strategies to maximize vaccination acceptance and ED distribution of vaccines in older adults should be
implemented.
ED providers must have access to multiple external sources to help incorporate the constantly
evolving treatments and recommendations, such as monoclonal antibodies and oral antivirals into ED
practice. These treatments are particularly useful in the care of older adults with mild to moderate
illnesses.
Psychosocial implications, care of those with dementia, and transitions to residential centers are
subjects that must be understood by emergency providers in order to provide competent care and
dispositions. The optimizing of professional functioning within the ED and maintaining both self-care and
care of your colleagues are important for the day-to-day survival of emergency providers under pandemicinduced stress.
Box 3: Patient Follow Up of Box 1- An Older Patient Presents to the ED for Treatment
•

Which medication or treatment could be considered?
This patient had acute onset of symptoms within a few days of presenting to her primary care provider for a routine
visit. She had laboratory-confirmed testing for COVID-19. Her vital signs, including pulse oximetry, were normal. There
was no sign of delirium, no functional decline, and no worsening of her co-morbid illnesses. The patient had received
her vaccination but did not receive her booster. Her age and co-morbidities put her at risk for severe disease. In this
case, sotrovimab was available and was administered in the ED. Oral molnupiravir would have been an alternative
treatment strategy.

•

How would you counsel the patient regarding her co-morbid illnesses?
This patient was counseled to continue with her routine medications and monitoring of her blood glucose. Her primary
care provider used a secure chat feature in the electronic health record to coordinate a follow-up visit in her office.
The patient was encouraged to schedule a COVID-19 booster in the community pharmacy in the next week. Her family
was provided the CDC website for guidance regarding their own testing and mask use.

Box 4: Patient Follow Up of Box 2- An Older Patient Presents to the ED for Treatment
•

What are common problems for older patients who have recently had COVID-19 infections?
Fatigue, anxiety, dyspnea, and headache are noted as common problems for those who have had COVID-19. These
symptoms may be attributed to the long-term scenario of COVID-19. In addition, older adults who have had an acute
illness are at risk of functional decline, with or without a COVID-19 illness. Further, a functional decline of an older
adult may signal an acute illness or an exacerbation of an underlying condition. A careful history, vital signs, a directed
physical examination, and diagnostic evaluation are in order. The ED clinician should concurrently direct attention to
her complaint of pain in her legs.

•

How would you determine the best strategy to help this older patient and her family caregivers?
This individual has several “red flags” which pose risk for her care. She has multiple co-morbid illnesses including
dementia and end-stage renal disease. She has not received her COVID-19 vaccination or booster and this poses a
particular risk for serious illness. She has missed dialysis in the context of her COVID-19 status. Now she needs more
help in transferring from her bed. Her daughter expresses caregiver strain. The best strategy in the ED is to define the
underlying problems contributing to her decline. The patient’s preferences for care should be elicited and “What
matters most?” Likewise, define if the patient has an advance directive.

•

How do we access community and long-term services to support this patient and family caregiver?
In this case, the first determination would be if she needs to be admitted or not. The daughter could further describe
efforts to access dialysis care. The ED staff should get a sense if the family is able and interested in having the patient
return home. With the ED boarding status, a social worker and physical therapist should be consulted while the patient
is in the ED.
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